<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HER reseptör ailesi &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/her-reseptor-ailesi/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 18 Jan 2026 23:50:43 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>HER reseptör ailesi &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Dual Antibody Therapy Overcomes Cetuximab Resistance</title>
		<link>https://bioengineer.org/dual-antibody-therapy-overcomes-cetuximab-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 23:50:43 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cetuximab direnci]]></category>
		<category><![CDATA[Çift hedefli antikor tedavisi]]></category>
		<category><![CDATA[HER reseptör ailesi]]></category>
		<category><![CDATA[Kanser tedavi direnci]]></category>
		<category><![CDATA[Kişiselleştirilmiş onkoloji]]></category>
		<guid isPermaLink="false">https://bioengineer.org/dual-antibody-therapy-overcomes-cetuximab-resistance/</guid>

					<description><![CDATA[Recent advances in cancer therapy have highlighted the importance of targeting specific receptors involved in tumor growth and progression. In particular, receptor tyrosine kinases, such as the HER family, play significant roles in various types of cancers, including colorectal cancer. One of the leading agents used in clinical practice is cetuximab, a monoclonal antibody that [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318074</post-id>	</item>
	</channel>
</rss>
